Adalimumab biosimilar drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Idacio® | |||
| INN | Adalimimab biosimilar | |||
| API type | Adalimumab is a biosimilar medicinal product. Is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells. | |||
| Pharmacotherapeutic group | Immunosuppressants, Tumour Necrosis Factor alpha (TNFα) inhibitors | |||
| ATC code | L04AB04 | |||
| Target of antibody | TNFα | |||
| General function | Adalimumab is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. Also indicate for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. | |||
| Short description | ||||
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration. | |||
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after adalimumab administration. | |||
| Original license holder | ||||
| Marketing authorisation numbers | EU/1/19/1356/001 | |||
| Marketing authorisation holder | Fresenius Kabi Deutschland GmbH Else-Kröner-Straße 1 61352 Bad Homburg v. d. Höhe | |||
| Name of the manufacturer of the biological active substance | Merck Serono S.A. Succursale de Corsier-sur-Vevey Chemin du Fenil Zone Industrielle B 1804 Corsier-sur-Vevey Switzerland | |||
| Name and address of the manufacturer(s) responsible for batch release | Fresenius Kabi Austria GmbH Hafnerstraße 36, 8055 Graz Austria | |||
| Max shelf life | 24 months | |||
| Storage conditions | 2°C – 8°C | |||
| List of excipients | Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Mannitol Sodium chloride Citric acid monohydrate Sodium citrate Polysorbate 80 Sodium hydroxide (for pH adjustment) Water for injections |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
